Le Lézard
Classified in: Health, Sports and recreation
Subjects: NEW PRODUCTS/SERVICES, HEALTH

L!X Modern Oral Nicotine Pouches Receive FDA Acceptance For Premarket Tobacco Product Application (PMTA)


PICKERING, Ontario, Jan. 12, 2023 (GLOBE NEWSWIRE) -- TJP Labs Inc. ("TJP Labs") is proud to announce the acceptance of its Premarket Tobacco Product Application (PMTA) submission by the U.S. Food and Drug Administration for its brand, L!X modern oral nicotine pouches. 

Marketed by its subsidiary L!X Innovations Inc. ("L!X Innovations"), under the name L!X nicotine pouches, the brand's application now moves forward to the next step in the PMTA review process.

Speaking on the occasion, David Richmond-Peck, CEO of TJP Labs, said: 

"The PMTA process is a highly competitive and rigorous science-based review, and acceptance of this application is a significant milestone in our global harm reduction strategy. We look forward to working with the FDA knowing our products have the potential to reduce harm for adult nicotine consumers.

TJP Labs committed strategically to the new modern oral market several years ago. As a result, our world-class manufacturing facility, robust quality management systems and flavor-rich formulations allow us to build solid foundations in the modern oral and beyond nicotine categories. I congratulate our quality, manufacturing and regulatory teams on their continued success. "

Speaking of this latest achievement, CEO of L!X Innovations, Waqas Khan, further noted: 

"When we set out on our journey of global harm reduction, we knew that we had to build a premium product that respected the heritage of Swedish snus and combined the benefits of the modern oral pouch format. Our various focus groups and consumer tests prove that L!X nicotine pouches, with their long-lasting flavor and smooth mouth feel, are one of the best options on the global market. We are confident our brand will quickly become the brand of choice for consumers globally."

About TJP Labs Inc. 
TJP Labs Inc. is North America's leading full-service contract manufacturer of premier next-generation products, focusing on modern oral nicotine pouches and oral delivery solutions for caffeine and other nutraceutical products. 

Our products are manufactured and packaged in our DEL, Site-Licensed, cGMP/HACCP compliant, ISO 9001:2015 certified state-of-the-art facilities.

Contacts
TJP Labs Inc. - business@tjplabs.com       Website: www.tjplabs.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16896913-ec4c-4943-9e50-2bc1106be461



These press releases may also interest you

at 22:30
The "Research Antibodies and Reagents Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the...

at 22:15
The "Healthcare E-Commerce Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The...

at 22:00
The bacterial disease diagnostics market size is forecast to grow by USD 3,766.05 million between 2022 and 2027. However, the growth momentum will be decelerating at a CAGR of 6.28% during the forecast period. The growth of the market is driven by...

at 21:18
Avirmax CMC Inc. (ACI), a cGMP-licensed CDMO, is announcing the implementation of its newly-developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVFtm) developed for producing recombinant adeno-associated viral vectors (rAAV)....

at 20:35
Biogen Inc.  announced today the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1...

at 20:30
The "Global Gene Editing Partnering Terms and Agreements 2010 to 2023" report has been added to  ResearchAndMarkets.com's offering. The Global Gene Editing Partnering Terms and Agreements 2010-2023 report provides an understanding and access to 400+...



News published on 12 january 2023 at 09:35 and distributed by: